MaaT Pharma SA announced that extended results from its Early Access Program (EAP) of MaaT013 in patients with GI-aGvHD have been selected for oral presentation at the 64thAmerican Society of Hematology (ASH) Annual Meeting held from December 10-13, 2022, in New-Orleans, Louisiana, U.S.A. Additionally, detailed results of the Phase 1b trial of MaaT033 in patients with acute myeloid leukemia (AML) were selected for presentation in a poster session. This is the sixth year in a row that the Company's clinical data are selected for presentation at the ASH Conference, the event in malignant and non-malignant hematology, and the third year in a row for an oral presentation. In line with the conference embargo policy, MaaT Pharma will detail the presented results through a press release on December 10, 2022.

The Company will also host an investor webcast on December 12th, 2022, at 6:00pm CET (additional details will be provided at a later date). The EAP results include data from 81 patients treated with MaaT013, with steroid-resistant or steroid-dependent aGvHD with GI involvement, who had previously failed 1 to 6 lines. About MaaT013: MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, enema Microbiome Ecosystem TherapyTM for acute, hospital use.

It is characterized by a consistently high diversity and richness of microbial species and the presence of ButycoreTM (group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 aims to restore the symbiotic relationship between the patient's functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

About MaaT033: MaaT033 is an oral, full-ecosystem, off-the-shelf, standardized, pooled-donor, high-richness Microbiome Ecosystem TherapyTM. MaaT033 is designed to restore the gut ecosystem to full functionality to improve clinical outcomes as well as to control adverse events related to conventional treatments for liquid tumors. The capsule formulation facilitates administration and allows the potential to treat larger patients' population while maintaining the high and consistent richness and diversity of microbial species, including anti-inflammatory ButycoreTM species.